Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

SciClone Pharma (6600 HK): Privatisation At IPO Price

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

SciClone Pharma (6600 HK): GL Capital Consortium Reload?

Quiddity Advisors

Event-Driven

<ul>
<li>On the 28th March, Li Zhenfu (<strong><a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-holdings-limited" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">SciClone (6600 HK)</a></strong>'s NED), <strong><a href="https://www.smartkarma.com/entities/assicurazioni-generali-spa" target="_blank" data-smartkarma-citation="entities:21191:1" rel="noopener">Assicurazioni Generali (G IM)</a></strong>, and concert parties (collectively controlling 36.61%), <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0328/2024032800746.pdf" target="_blank" rel="noopener">made an Offer at $18.80/share</a>, a 33.9% premium to undisturbed. </li>
<li>The Offer price is bang in line with SciClone's March 2021 IPO price. Terms were declared final. This is a clean deal.</li>
<li>The <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0523/2024052301651.pdf" target="_blank" rel="noopener">Scheme Document</a> is now out. The Court Meeting will be held on the 19th June. Expected payment on or before the 12 July. FWIW: IFA says fair &amp; reasonable.</li>
</ul>


On the 28th March, Li Zhenfu (SciClone (6600 HK)'s NED), Assicurazioni Generali (G IM), and concert parties (collectively controlling 36.61%), made an Offer at $18.80/share, a 33.9% premium to undisturbed. 
The Offer price is bang in line with SciClone's March 2021 IPO price. Terms were declared final. This is a clean deal.
The Scheme Document is now out. The Court Meeting will be held on the 19th June. Expected payment on or before the 12 July. FWIW: IFA says fair &amp; reasonable.


SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote

Sciclone Pharmaceuticals

SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote